Log in

NASDAQ:ICCCImmuCell Stock Price, Forecast & News

$5.48
+0.06 (+1.11 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.09
Now: $5.48
$5.64
50-Day Range
$4.02
MA: $4.56
$5.49
52-Week Range
$3.70
Now: $5.48
$8.13
Volume7,500 shs
Average Volume57,965 shs
Market Capitalization$39.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICCC
CUSIPN/A
Phone207-878-2770

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.72 million
Cash Flow$0.14 per share
Book Value$4.02 per share

Profitability

Net Income$-1,300,000.00

Miscellaneous

Employees47
Market Cap$39.53 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.

ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

How has ImmuCell's stock been impacted by COVID-19 (Coronavirus)?

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ICCC shares have increased by 27.4% and is now trading at $5.48. View which stocks have been most impacted by Coronavirus.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for ImmuCell.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) released its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($0.02) earnings per share for the quarter. The biotechnology company earned $4.91 million during the quarter. ImmuCell had a negative return on equity of 5.35% and a negative net margin of 10.98%. View ImmuCell's earnings history.

Has ImmuCell been receiving favorable news coverage?

News articles about ICCC stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ImmuCell earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about ImmuCell.

Are investors shorting ImmuCell?

ImmuCell saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,200 shares, an increase of 223.1% from the June 15th total of 1,300 shares. Based on an average trading volume of 27,500 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the shares of the company are sold short. View ImmuCell's Current Options Chain.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Who are ImmuCell's key executives?

ImmuCell's management team includes the following people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
  • Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $5.48.

How big of a company is ImmuCell?

ImmuCell has a market capitalization of $39.53 million and generates $13.72 million in revenue each year. ImmuCell employs 47 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is www.immucell.com.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.